In a brief statement released following Monday's market close, Sarepta Therapeutics Inc. revealed that the FDA requested additional dystrophin data as part of its ongoing review of the new drug application (NDA) for Duchenne muscular dystrophy (DMD) candidate, eteplirsen. According to Sarepta, the agency said the dystrophin data, as measured by Western blot, could be acquired from biopsies already obtained from PROMOVI, the ongoing confirmatory study of eteplirsen.